CF
RXRX icon

CNA Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

CNA Financial’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,112
Closed -$257K – 146
2022
Q3 		$257K Sell
24,112
-5,360
-18% -$54.3K 0.1% 150
2022
Q2 		$240K Buy
29,472
+800
+3% +$5.35K 0.08% 163
2022
Q1 		$205K Buy
28,672
+2,890
+11% +$30.7K 0.06% 179
2021
Q4 		$442K Buy
25,782
+9,250
+56% +$174K 0.12% 169
2021
Q3 		$380K Buy
16,532
+3,100
+23% +$87.9K 0.1% 179
2021
Q2 		$490K Buy
+13,432
New +$398K 0.14% 164

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

CNA Financial's RXRX Position: Q4 2022 in Review

CNA Financial sold out of Recursion Pharmaceuticals (RXRX) in Q4 2022, closing a stake of 24,112 shares — an estimated $257K sold.

CNA Financial first reported a position in RXRX in Q2 2021 and held it in 6 quarters. The position peaked at $490K in Q2 2021. 144 funds tracked by Wall St. Rank hold RXRX as of Q4 2022.

  • CNA Financial reported no remaining Recursion Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • CNA Financial sold 24,112 Recursion Pharmaceuticals shares in Q4 2022, an estimated $257K.
  • CNA Financial first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 6 quarters.
  • CNA Financial's Recursion Pharmaceuticals position peaked at $490K in Q2 2021.
  • 144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2022.

Based on CNA Financial's 13F filing for Q4 2022, filed 10 Feb 2023.